ProFound Therapeutics Named ‘Fierce 15’ Company of 2024 by Fierce Biotech

ProFound™ Therapeutics, a Flagship-founded company pioneering the expanded human proteome to develop novel medicines for a multitude of diseases, today announced it was named one of Fierce Biotech’s ‘Fierce 15’ companies of 2024. The annual list highlights the most promising early-stage biotechnology companies in the industry.

“For the ProFound team, being honored on such a prestigious list alongside this year’s esteemed emerging biotech companies further underscores the promise of our ProFoundry Platform and our steadfast commitment to advancing novel therapeutic solutions for patients,” said John Lepore, M.D., CEO of ProFound Therapeutics and Flagship Pioneering CEO-Partner. “The expanded human proteome offers a vast universe of untapped therapeutic potential, and we are looking forward to continuing to grow our understanding of these proteins to produce first-in-class medicines for patients in need.”

The Human Genome Project identified approximately 20,000 unique proteins encoded within only 2% of the 3 billion base pairs that make up our DNA. ProFound has uncovered tens of thousands of additional proteins within the expanded proteome via its ProFoundry^TM Platform, which integrates industrialized state-of-the-art protein discovery technologies, high-throughput functional validation, and cutting-edge computational tools. The platform yields an ever-expanding database of novel proteins, including their connectivity, functionality, and roles in health and disease – resulting in a vast new pool of potential protein drugs and targets that hold promise as first-in-class medicines.

Each year, Fierce Biotech celebrates the 15 ‘fiercest’ companies championing innovation and creativity in the biotechnology industry, even in the face of intense competition. To see this year’s full list of honorees, read here: https://www.fiercebiotech.com/special-reports/introducing-fierce-biotechs-2024-fierce-15